相关实验视频

Updated: Jul 28, 2025

Confocal Imaging of Neuropeptide Y-pHluorin: A Technique to Visualize Insulin Granule Exocytosis in Intact Murine and Human Islets

Confocal Imaging of Neuropeptide Y-pHluorin: A Technique to Visualize Insulin Granule Exocytosis in Intact Murine and Human Islets

Published on: September 13, 2017

用于可视化和控制高时空分辨率的人类GLP-1受体激活的光学工具

Loïc Duffet¹, Elyse T Williams², Andrea Gresch¹

¹Institute of Pharmacology and Toxicology, University of Zürich, Zurich, Switzerland.

|June 2, 2023

概括

研究人员开发了GLPLight1,这是一种用于葡萄糖样-1受体 (GLP1R) 的新型光传感器. 这种工具可以对GLP1R激活动态进行精确的,高分辨率的研究,这对于理解代谢调节和药物开发至关重要.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

葡萄糖类-1受体 (GLP1R) 对于葡萄糖和能量平衡至关重要.
GLP1R是主要减肥药物,如塞马格卢提德和利拉格卢提德的目标.
目前的工具缺乏时空分辨率,无法准确地研究GLP1R激活动态.

研究的目的:

开发一种新的基因编码传感器,用于高分辨率GLP1R活动监测.
建立一个全光学试验,以表征GLP1R配体和激活.
加强研究GLP1R的形状变化和信号通路.

主要方法:

在人类GLP1R中设计一个循环 permuted 绿色光蛋白,以创建GLPLight1.
利用光信号的变化来报告受体的 conformational 激活.
开发一个全光学测试用于光GLP-1衍生品的特征.

主要成果:

GLPLight1准确地报告了GLP1R的 conformational激活,具有高灵敏度 (最大 ΔF/F0=528%) 和时间分辨率 (τON = 4.7 秒).
GLPLight1表现出与GLP-1衍生品相似的反应,作为原生受体.
成功描述了光GLP-1衍生物,并证明了GLP1R的光学控制.

结论:

GLPLight1是一个敏感和高分辨率的工具,用于研究GLP1R激活.
开发的全光学工具包推动了GLP1R信号的研究.
这项技术对理解代谢疾病和优化基于GLP1R的治疗方法有影响.

关键词:

这就是GLP1RR.生物化学生物化学化学生物学化学生物学光是一种光.基因编码的传感器传感器人类人类人类人类人类人类人类这里是鼠标鼠标鼠标鼠标鼠标鼠标.这是一种神经,神经.摄影中的照片

更多相关视频

High-resolution Spatiotemporal Analysis of Receptor Dynamics by Single-molecule Fluorescence Microscopy

High-resolution Spatiotemporal Analysis of Receptor Dynamics by Single-molecule Fluorescence Microscopy

Published on: July 25, 2014

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...